» Articles » PMID: 6188527

Determination of Circulating DNA Levels in Patients with Benign or Malignant Gastrointestinal Disease

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 1983 Jun 1
PMID 6188527
Citations 108
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies showed that patients with neoplasms of various types and origins have abnormally high concentration of DNA in their serum. The current work compares circulating DNA levels in patients with benign or malignant disease of the gastrointestinal tract and determines the diagnostic value of such measurements. DNA was quantitated by radioimmunoassay capable of detecting 25 ng/ml, and as a simple and noninvasive test, it could be a useful addition to other diagnostic procedures. The GI tract was chosen because it affords a comparison of benign, precancerous, and malignant lesions of the same organ. Of the 386 patients studied prospectively, 48% had benign disease and mean DNA levels (+/- SE) of 118 +/- 14 ng/ml, whereas 52% had malignant disease and 412 +/- 63 ng DNA/ml. The difference was statistically significant (P less than 0.001). The DNA assay showed the highest sensitivity for pancreas carcinoma: 90% of the patients had DNA levels above 100 ng/ml, chosen as the upper normal limit. Simultaneous measurements of both DNA and carcinoembryonic antigen (CEA) resulted in increased sensitivity and specificity, even when either marker alone had low sensitivity (gastric carcinoma). The results indicate that serum DNA concentration is markedly elevated in malignancy, and moderately elevated in benign disease, as compared with normal controls. These findings may have diagnostic and prognostic value.

Citing Articles

Impact of Molecular Profiling on Therapy Management in Breast Cancer.

Ultimescu F, Hudita A, Popa D, Olinca M, Muresean H, Ceausu M J Clin Med. 2024; 13(17).

PMID: 39274207 PMC: 11396537. DOI: 10.3390/jcm13174995.


Targeted Nanoparticle-Based Diagnostic and Treatment Options for Pancreatic Cancer.

Gu X, Minko T Cancers (Basel). 2024; 16(8).

PMID: 38672671 PMC: 11048786. DOI: 10.3390/cancers16081589.


A Quest for Survival: A Review of the Early Biomarkers of Pancreatic Cancer and the Most Effective Approaches at Present.

Bestari M, Joewono I, Syam A Biomolecules. 2024; 14(3).

PMID: 38540782 PMC: 10968439. DOI: 10.3390/biom14030364.


A Comprehensive Review of the Potential Role of Liquid Biopsy as a Diagnostic, Prognostic, and Predictive Biomarker in Pancreatic Ductal Adenocarcinoma.

Stosic K, Azurmendi Senar O, Tarfouss J, Bouchart C, Navez J, Van Laethem J Cells. 2024; 13(1).

PMID: 38201207 PMC: 10778087. DOI: 10.3390/cells13010003.


Nonspecificity fingerprints for clinical-stage antibodies in solution.

Herling T, Invernizzi G, Ausserwoger H, Rose Bjelke J, Egebjerg T, Lund S Proc Natl Acad Sci U S A. 2023; 120(52):e2306700120.

PMID: 38109540 PMC: 10756282. DOI: 10.1073/pnas.2306700120.